Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iadademstat + atezolizumab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Iadademstat + atezolizumab is an investigational combination regimen consisting of iadademstat (ORY-1001), a small-molecule inhibitor of lysine-specific demethylase 1 (LSD1), and atezolizumab (Tecentriq), a programmed death-ligand 1 (PD-L1) blocking monoclonal antibody. Developed by Oryzon Genomics in collaboration with Genentech, this combination is being evaluated for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The therapeutic rationale relies on iadademstat's epigenetic modulation, which increases the immunogenicity of SCLC cells by making them visible to the immune system and promoting the infiltration and activation of cytotoxic CD8+ T cells, thereby enhancing the anti-tumor efficacy of the immune checkpoint inhibitor atezolizumab. The combination is currently undergoing Phase I/II clinical evaluation, including studies sponsored by the National Cancer Institute (NCI) and investigator-initiated trials at Yale University.
- Other names
- atezolizumab + iadademstatiadademstat and atezolizumabiadademstat combined with atezolizumab
02
Targets
KDM1A (LSD1)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on iadademstat + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iadademstat + atezolizumab.